University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Designing malaria vaccines to circumvent antigen variability

    Thumbnail
    Download
    Published version (512.8Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    26
    26
    Author
    Ouattara, A; Barry, AE; Dutta, S; Remarque, EJ; Beeson, JG; Plowe, CV
    Date
    2015-12-22
    Source Title
    Vaccine
    Publisher
    ELSEVIER SCI LTD
    University of Melbourne Author/s
    Barry, Alyssa
    Affiliation
    Medical Biology (W.E.H.I.)
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Ouattara, A., Barry, A. E., Dutta, S., Remarque, E. J., Beeson, J. G. & Plowe, C. V. (2015). Designing malaria vaccines to circumvent antigen variability. VACCINE, 33 (52), pp.7506-7512. https://doi.org/10.1016/j.vaccine.2015.09.110.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/258060
    DOI
    10.1016/j.vaccine.2015.09.110
    Abstract
    Prospects for malaria eradication will be greatly enhanced by an effective vaccine, but parasite genetic diversity poses a major impediment to malaria vaccine efficacy. In recent pre-clinical and field trials, vaccines based on polymorphic Plasmodium falciparum antigens have shown efficacy only against homologous strains, raising the specter of allele-specific immunity such as that which plagues vaccines against influenza and HIV. The most advanced malaria vaccine, RTS,S, targets relatively conserved epitopes on the P. falciparum circumsporozoite protein. After more than 40 years of development and testing, RTS,S, has shown significant but modest efficacy against clinical malaria in phase 2 and 3 trials. Ongoing phase 2 studies of an irradiated sporozoite vaccine will ascertain whether the full protection against homologous experimental malaria challenge conferred by high doses of a whole organism vaccine can provide protection against diverse strains in the field. Here we review and evaluate approaches being taken to design broadly cross-protective malaria vaccines.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [53102]
    • Medical Biology - Research Publications [1415]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors